TEVA PHARMACEUTICAL IN

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

20 5 2025 14:21:57 提供 Nasdaq GlobeNewswire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

20 5 2025 13:30:00 提供 Nasdaq GlobeNewswire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

19 5 2025 01:52:49 提供 Nasdaq GlobeNewswire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

19 5 2025 01:52:13 提供 Nasdaq GlobeNewswire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

15 5 2025 15:12:28 提供 Nasdaq GlobeNewswire

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

12 5 2025 04:00:00 提供 Nasdaq GlobeNewswire

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

07 5 2025 04:00:00 提供 Nasdaq GlobeNewswire

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

07 5 2025 04:00:00 提供 Nasdaq GlobeNewswire

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

05 5 2025 04:49:08 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

10 4 2025 09:37:35 提供 NetDania Notify

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

07 4 2025 05:00:00 提供 Nasdaq GlobeNewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

07 4 2025 04:30:52 提供 Nasdaq GlobeNewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

31 3 2025 10:00:00 提供 Nasdaq GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

27 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

Teva Releases Q1 2025 Aide Memoire

27 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

03 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

27 2 2025 05:00:00 提供 Nasdaq GlobeNewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

25 2 2025 13:00:00 提供 Nasdaq GlobeNewswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

21 2 2025 23:20:00 提供 Nasdaq GlobeNewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

21 2 2025 03:00:00 提供 Nasdaq GlobeNewswire